PURPOSE: This study describes the pharmacokinetics, safety, and tolerability of ribavirin in hemodialysis-dependent patients. METHODS: Six adult patients (4 male, 2 female) were recruited from a hemodialysis clinic where they were receiving regular hemodialysis sessions. Patients received a single oral 400-mg dose of ribavirin (2 × 200-mg capsules) after an overnight fast. A 4-h hemodialysis session was performed between 6 and 10 h post-dose. Plasma and urinary concentrations of ribavirin were determined using validated high-performance liquid chromatography/tandem mass spectrometric methods. RESULTS: Single oral doses of ribavirin 400 mg were safe and well tolerated in this population. Urinary excretion of ribavirin over 48 h was minimal (0.6 mg: approximately 0.14% of the dose). The mean amount removed during the 4-h hemodialysis session (9.6 mg) represented approximately 2.4% of the dose. CONCLUSIONS: Ribavirin hemodialysis clearance (CLhd = 74.5 ml/min) represented approximately 50% of the renal clearance (CLr) measured in subjects with normal renal function (CLr = 129 ml/min).
PURPOSE: This study describes the pharmacokinetics, safety, and tolerability of ribavirin in hemodialysis-dependent patients. METHODS: Six adult patients (4 male, 2 female) were recruited from a hemodialysis clinic where they were receiving regular hemodialysis sessions. Patients received a single oral 400-mg dose of ribavirin (2 × 200-mg capsules) after an overnight fast. A 4-h hemodialysis session was performed between 6 and 10 h post-dose. Plasma and urinary concentrations of ribavirin were determined using validated high-performance liquid chromatography/tandem mass spectrometric methods. RESULTS: Single oral doses of ribavirin 400 mg were safe and well tolerated in this population. Urinary excretion of ribavirin over 48 h was minimal (0.6 mg: approximately 0.14% of the dose). The mean amount removed during the 4-h hemodialysis session (9.6 mg) represented approximately 2.4% of the dose. CONCLUSIONS:Ribavirin hemodialysis clearance (CLhd = 74.5 ml/min) represented approximately 50% of the renal clearance (CLr) measured in subjects with normal renal function (CLr = 129 ml/min).
Authors: A C Tan; J T Brouwer; P Glue; R van Leusen; R H Kauffmann; S W Schalm; R A de Vries; B Vroom Journal: Nephrol Dial Transplant Date: 2001-01 Impact factor: 5.992
Authors: Maria Rendina; Antonio Schena; Nicola Maurizio Castellaneta; Francesco Losito; Anna Cinzia Amoruso; Giovanni Stallone; Francesco Paolo Schena; Alfredo Di Leo; Antonio Francavilla Journal: J Hepatol Date: 2007-02-05 Impact factor: 25.083
Authors: E Singlas; A M Taburet; F Borsa Lebas; O Parent de Curzon; A Sobel; P Chauveau; B Viron; R al Khayat; J L Poignet; F Mignon Journal: Antimicrob Agents Chemother Date: 1992-07 Impact factor: 5.191
Authors: Robert van Leusen; Rob P R Adang; Richard A de Vries; Trijntje T Cnossen; Constantijn J A M Konings; Solko W Schalm; Adriaan C I T L Tan Journal: Nephrol Dial Transplant Date: 2007-11-27 Impact factor: 5.992
Authors: Joseph E Rower; Eric G Meissner; Leah C Jimmerson; Anu Osinusi; Zayani Sims; Tess Petersen; Lane R Bushman; Pamela Wolfe; John G McHutchison; Shyamasundaran Kottilil; Jennifer J Kiser Journal: J Antimicrob Chemother Date: 2015-05-13 Impact factor: 5.790
Authors: Markus Zeitlinger; Birgit C P Koch; Roger Bruggemann; Pieter De Cock; Timothy Felton; Maya Hites; Jennifer Le; Sonia Luque; Alasdair P MacGowan; Deborah J E Marriott; Anouk E Muller; Kristina Nadrah; David L Paterson; Joseph F Standing; João P Telles; Michael Wölfl-Duchek; Michael Thy; Jason A Roberts Journal: Clin Pharmacokinet Date: 2020-10 Impact factor: 6.447
Authors: Clara T M M de Kanter; Joost P H Drenth; Joop E Arends; Henk W Reesink; Marc van der Valk; Robert J de Knegt; David M Burger Journal: Clin Pharmacokinet Date: 2014-05 Impact factor: 5.577